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Neutrophilic dermatoses (ND) are a polymorphous group of noncontagious dermatological disorders that share the common
histological feature of a sterile cutaneous infiltration ofmature neutrophils. Clinicalmanifestations can vary fromnodules, pustules,
and bulla to erosions and ulcerations. The etiopathogenesis of neutrophilic dermatoses has continuously evolved. Accumulating
genetic, clinical, and histological evidence point toNDs being classified in the spectrumof autoinflammatory conditions. However,
unlike the monogenic autoinflammatory syndromes where a clear multiple change in the inflammasome structure/function is
demonstrated, NDs display several proinflammatory abnormalities, mainly driven by IL-1, IL-17, and tumor necrosis factor-alpha
(TNF-a). Additionally, because of the frequent association with extracutaneous manifestations where neutrophils seem to play a
crucial role, it was plausible also to consider NDs as a cutaneous presentation of a systemic neutrophilic condition. Neutrophilic
dermatoses are more frequently recognized in association with respiratory disorders than by chance alone.The combination of the
two, particularly in the context of their overlapping immune responses mediated primarily by neutrophils, raises the likelihood of
a common neutrophilic systemic disease or an aberrant innate immunity disorder. Associated respiratory conditions can serve as
a trigger or may develop or be exacerbated secondary to the uncontrolled skin disorder. Physicians should be aware of the possible
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pulmonary comorbidities and apply this knowledge in the three steps of patients’ management, work-up, diagnosis, and treatment.
In this review, we attempt to unravel the pathophysiological mechanisms of this association and also present some evidence for the
role of targeted therapy in the treatment of both conditions.
1. Introduction
The idea of a greater understanding of how body organs
operate in interconnected ways to influence the homeostatic
capacities of one another is gaining attention in modern
medicine [1]. One such example arises from the physio-
logical and pathological relationship between the skin and
respiratory systems. Continual accumulating evidence sup-
ports the idea that these two systems are uniquely related
in function [2]. As a primary interface with the outside
world, both are equipped with specialized immune defenses
and colonized by microbial commensals, crucial factors in
regulating and maintaining homeostasis. Additionally, west-
ern medicine has observed interesting associations of some
chronic inflammatory dermatoses with both allergic and
nonallergic respiratory conditions [3, 4]. In this discussionwe
investigate the relationship between neutrophilic dermatoses
and respiratory disorders in order to demonstrate the impact
of neutrophils in this associated comorbidity. We also attempt
to shed light on potential strategies for optimizing the
management of both conditions [5].
2. Neutrophilic Dermatoses
Neutrophilic dermatoses (ND) are a polymorphous group
of noncontagious dermatological disorders that share the
common histological feature of a sterile cutaneous infil-
tration with mature normal neutrophils [6, 7]. Clinical
manifestations can vary from nodules, pustules, and bulla
to erosions and ulcerations. Furthermore, NDs can be his-
tologically subcategorized according to predominance of
the neutrophilic infiltrate in different skin layers into (1)
epidermal NDs as seen in pustular psoriasis, IgA pemphi-
gus, acute generalized exanthematous pustulosis (AGEP),
a microbial pustulosis of the folds, and a microbial pus-
tulosis of the scalp; (2) dermal NDs as in acute febrile
neutrophilic dermatosis or Sweet’s syndrome (SS), erythema
elevatum diutinum, and neutrophil eccrine hidradenitis; and
(3) dermo-hypodermal NDs as in hidradenitis suppurativa
(HS), neutrophilic panniculitis, aseptic abscesses syndrome,
and pyoderma gangrenosum (PG). Despite the fact that the
etiology of ND is often idiopathic, interesting associations
have been found with other systemic preceding illnesses.
Common examples include the frequent finding of Sweet
syndrome with myeloid hematologic malignancies and the
eruption of pyoderma gangrenosum inpatientswith rheuma-
toid arthritis and inflammatory bowel disease, separately
and sometimes together. Similarly, cases of erythema ele-
vatum diutinum and subcorneal pustular dermatosis were
reported with monoclonal gammopathies (erythema eleva-
tum diutinum, subcorneal pustular dermatosis). These obser-
vations draw attention to a possible infiltration of interior
organs with neutrophils during the establishment of ND,
thus promoting the notion of neutrophilic systemic disease
[8, 9]. The etiopathogenesis of NDs is still debatable. NDs
do indeed share some pathogenetic and clinical features
with autoinflammatory diseases, defined as conditions that
manifest themselves as recurrent episodes of inflammation
in targeted organs, without evidence of infection, high titer
of circulating autoantibodies, and T autoreactive cells, unlike
the monogenic autoinflammatory syndromes where a clear
alteration in the inflammasome structure/function is demon-
strated. NDs display several proinflammatory alterations
mainly driven by IL-1, IL-17, and tumor necrosis factor-alpha
(TNF-a); however these remain an important matter for
discussion, mainly because of their rarity and difficulties in
diagnosing. What remains certain is the role of dysregulated
PMNs homeostasis in the development of cutaneous and
extracutaneous manifestations in NDs [10–13]. The main
NDs with their respiratory comorbidities are summarized in
Table 1.
2.1. The Role of Neutrophils in the Pathogenesis of Neutrophilic
Dermatoses. Neutrophils represent the main component of
white blood cells (WBCs) and constitute the first line of
defense against external as well as internal insults. During
acute inflammation, neutrophils are the first immune cells
to migrate from the blood to the site of inflammation
site by chemotaxis. Elimination of pathogens occurs by
means of phagocytosis, formation of neutrophil extracellular
traps (NETs), and the production of antimicrobial granules.
Furthermore, neutrophils are crucial to the expansion and
provocation of inflammatory responses through the release
of chemokines and cytokines resulting in the recruitment and
activation of more neutrophils in addition to other innate and
adaptive immune cells such asmacrophages and natural killer
cells, T helper type 1 (Th1) andTh17 cells [14].
Although this progression is necessary to mount an
effective immune reaction aimed at clearing invaders, the
accompanied inflammation is often detrimental to the host
cells and can end in serious pathological conditions because
of the uncontrolled, persistent activation of neutrophils and
the innate response. This can lead to a more chronic inflam-
mation and ultimately tissue destruction. Therefore, tight
regulation of neutrophil migration and activation is pivotal
[14]. Recently neutrophilic dermatoses have been linked to
the concept of autoinflammation. Mounting evidence of a
common cytokine profile including IL-1 beta, TNF, and
IL-17 in the lack of any evidence of allergy, infection, or
autoimmunity has supported this argument. In addition, the
identification of multiple overlapping genetic, clinical and
histologic features with autoinflammatory conditions further
validates this theory. Additionally, the frequent association of
NDs with systemic inflammatory diseases where neutrophils
seem to play a prominent role promotes the idea of NDs
being a polygenic cutaneous autoinflammatory condition
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with a potential neutrophilic infiltration of interior organs
resulting in a neutrophilic systemic disorder [14–16]. In
support of this hypothesis was the efficacy of interleukin-
1 (IL-1) blocking therapeutic agents in the management
of some neutrophilic dermatoses [9]. Being aware of this
connection will provide new insights into the treatment
of refractory comorbidities encountered with neutrophilic
dermatoses. Inflammasomes are understood as fundamental
in the pathogenesis of autoinflammatory disease. These cyto-
plasmic proteins critically regulate the proteolytic cleavage
and activation of IL-1 beta and IL-18, strong proinflammatory
cytokines. Activation of IL-1 beta production requires two
signals. The first is a priming signal to induce the expression
of the pro-IL-1, occurring as a result of the activation of
myeloid differentiation gene 88 (MyD88) dependent nuclear
factor (NF)-KBmediated by stimulation of Toll like receptors
(TLRs), and then full activation of inflammasome complex is
achieved when its cytoplasmic pattern recognition receptors
receive either damage or pattern associated molecular pattern
signals. As a result, caspase-1 is activated which in turn
processes pro-IL-1 into functional IL-1. Once formed, active
IL-1 signaling then amplifies neutrophil mediated inflam-
mation through multiple mechanisms. Further, IL-1b has
antiapoptotic effects onneutrophils prolonging their survival;
neutrophils in turn increase the activation of Pro-IL-1 to
mature IL-1b in both inflammasome dependent (caspase-
1 dependent) and/or inflammasome independent manner
through the release of elastase, proteinase-3, and cathepsin
G serine proteases. Additionally, enhancement of neutrophil
recruitment and activation can occur directly and indirectly
through IL-1 driving Th17 immune response [10, 14].
2.1.1. Association of Neutrophilic Dermatoses with Respiratory
Comorbidities. The link between neutrophilic dermatoses
and respiratory comorbidities, particularly in the context of
their overlapping immune responses mediated primarily by
neutrophils, raises the likelihood of a common neutrophilic
systemic disease or an aberrant innate immunity disorder.
The following observations are representative of the impor-
tance of neutrophilic dermatoses in lung-associated clinical
presentations and how this can be used to optimize patients’
management.
2.2. Hidradenitis Suppurativa and Associatedn
Respiratory Comorbidities
2.2.1. Hidradenitis Suppurativa (HS). Hidradenitis suppura-
tiva (HS) is a rare chronic inflammatory disease typically
affecting hair follicles often with a long delay before diagnosis
[17]. In order to overcome the delay, several questionnaires
were developed such as the visual aided questionnaire that
includes a group of specific questions and lesion images
[18]. HS is characterized by recurrent formation of multi-
ple abscesses and draining sinuses in apocrine, commonly
inguinal, anogenital, and axillary areas, and is therefore
referred to as acne inversa. Eventually these lesions heal with
scarring and disfigurement. Recent evidence has shown HS
extending beyond being a disfiguring dermatosis and rather a
systemic inflammatory disease with predominant cutaneous
presentation [19, 20]. Furthermore, a scoring system, named
Autoinflammatory Disease Damage Index (ADDI), capable
of accurately evaluating inflammatory-related comorbidities
has been also proposed [21].
Hyperkeratosis induced occlusions, and subsequent
inflammation of the pilosebaceous unit, together with the
dysregulated innate and adaptive immune responses, is a key
feature in the pathogenesis of HS. Occluded hair follicles
eventually rupture, spilling their contents, including bacteria
and keratin debris, into the surrounding dermal tissue
resulting in the chemotaxis of neutrophils and lymphocytes.
The recruited cellular infiltrate results in abscess formation
and destruction of the hair follicles and the surrounding
adnexal structures [22]. The role of the Notch signaling
pathway in the pathogenesis of HS was recently investigated
by Melnik and Plewig in 2013 [23]. A defect found in the
Notch pathway thought to be necessary for maintaining
the structure of the hair follicle appendage results in the
alteration of toll like receptor signaling inducing the release
of proinflammatory cytokines, such as tumor necrosis factor
(TNF)-𝛼, interleukin (IL)-1𝛽, and IL-17, thus promoting a
Th17 mediated immune response [10, 23].
2.2.2. Association of HS with Neutrophilic Asthma and COPD.
The importance of increased airway neutrophil infiltration
has long been identified as a cardinal feature of a number
of inflammatory pulmonary conditions such as COPD, inter-
stitial pneumonia [24], and asthma, especially severe forms
exacerbated by cigarette smoking [25].
A cross-sectional study performed by Magun et al.,
using Clalit Health Services database (CHS), investigated the
frequency of pulmonary diseases in 3207 patients with HS
compared to 6412 matched controls. The authors reported
a significant association of HS with asthma and chronic
obstructive pulmonary disease (COPD) which could be
explained by pulmonary neutrophil infiltration metastasizing
from skin conditions triggered by genetic and environmen-
tal factors known to enhance neutrophil chemotaxis and
increase their survival in the airways [26]. Furthermore,
increased levels of the proinflammatory cytokines such
as interleukin (IL)-17 and tumor necrosis factor (TNF)-𝛼
could directly contribute to airway inflammation [17]. No
correlation is actually demonstrated between HS severity and
respiratory involvement.
2.2.3. Role of Neutrophils in the Pathogenesis of Asthma. Neu-
trophils have also been linked to a subset of asthma referred
to as neutrophilic asthma which is often unresponsive to
steroid treatment. In 2010, Uddin et al. correlated the severity
of asthma to the neutrophil burden within the airways sec-
ondary to the presence of antiapoptotic factors increasing the
survival of polymorphonuclear leukocytes in the airway [27].
Baines et al. showed increased neutrophil chemotaxis and
survival in noneosinophilic asthma, a type commonly pop-
ulated withMoraxella catarrhalis orHaemophilus influenzae.
H. influenzae, in particular, is believed to driveTh17-mediated
development of neutrophilic asthma through the increase
6 BioMed Research International
of IL-17 production [28]. IL-17 levels are directly correlated
with a rise in IL-8 and other neutrophil chemotactic factors.
This cascade is exacerbated further by smoking and other
environmental antigens which also act as triggering factors
forHS too [29]. Infiltrating neutrophils subsequently produce
reactive oxygen species (ROS), IL-33, and TSLP (thymic
stromal lymphopoietin), which further perpetuate airway
inflammation. Additionally, allergens induce the release of
matrix metalloproteinase 9 (MMP9) and chemokines as
CXCL8 through the activation of toll like receptors 7 and
8 (TLR-7&8). Their release can in turn recruit more neu-
trophils in a positive feedback manner. Although clearance
of inflammatory cells through programmed cell death and
removal of cellular debris are a perquisite step of healing,
inappropriate neutrophilic necrosis or the failure of apoptosis
may instead enhance ongoing inflammation. Further, some
environmental antigens such as house dust mites (HDM-
DP) induce the production of myeloid-related protein 8 and
14 which in turn stimulate TLR4/Lyn/PI3K/Akt/ERK/NF-
kappaB pathway resulting in increased neutrophil survival
due to apoptosis inhibition [29].
2.2.4. Role of Neutrophils in the Pathogenesis of COPD.
According to World Health Organization (WHO), chronic
obstructive pulmonary disease (COPD) was reported as the
fifth leading cause of death globally, carrying a substan-
tial economic and health burden [30]. While the role of
neutrophils is confined to certain subtypes of asthma, their
contribution in COPD is crucial to disease pathogenesis
and the degree of their activation is directly related to the
severity of the clinical outcome. For example, increased
neutrophil lymphocyte ratio is a reliable predictor of a
potential exacerbation. In COPD, neutrophil released pro-
teases are believed to increase pathogen replication through
the impairment of the IL-22/IL22R defense mechanism
and downregulation of effector antimicrobial molecules like
𝛽defensin-2, ultimately resulting in acute progression. Addi-
tionally, the breakdown of lung elastin by neutrophil derived
elastase directly contributes to the inflammatory process of
COPD by diminishing the lung’s ability to tolerate infla-
tion sufficiently. Additionally, tumor necrosis factor-alpha
(TNF-𝛼) released by neutrophils upregulates the expression
of epidermal growth factor receptors on airway epithelial
goblet cell, resulting in mucus hypersecretion thereby fur-
ther exacerbating airway obstruction. Moreover, the reactive
oxygen species and elastases produced by the neutrophils
activate the pro-ligand transforming growth factor (TGF)
[31].
Cigarette smoking (CS) further worsens the prognosis in
both HS and COPD by increasing the release of damage-
associated molecular patterns (DAMPs)which, upon binding
to TLR 2, 4, and 9, enhance neutrophil recruitment and
activation and decrease apoptosis. However, this increase in
neutrophilic infiltration is not accompanied by elimination
of the pathogen as might be expected. CS results in defective
phagocytic activity by the means of inhibition of caspase-3,
which ultimately results in persistent infection and delayed
healing [29].
2.2.5. Implications of This Association on Treatment Strategies.
In the context of the aforementioned findings, it is plausible
to link nonresponsive cases of HS and COPD to the concept
of failed removal of excess detrimental neutrophils and that
neutrophilic targeted therapy could treat both conditions
simultaneously. Consistent with this hypothesis are the find-
ings reported by Tian et al., in 2017. This paper stressed the
importance of the granulocyte (neutrophil and eosinophils)
apoptosis and clearance for successful elimination of aller-
gen driven airway inflammation among those with steroid-
resistant inflammatory respiratory illness [32]. This may be
further supported by the observation of improved asthma
symptoms with SCH527132, a selective CXCR2 receptor
blocker that decreases neutrophils infiltration [33]. Similarly,
Anakinra, an IL-1 receptor antagonist, has shown promising
results in the treatment ofHS.Anopen-label study conducted
by Leslie et al. in 2014 involved the treatment of 6 HS patients
with Anakinra for 8 weeks followed by observation of their
lesions for another 8 weeks. Results revealed an improvement
of HS lesions in all the participants who completed the
eight-week trial [34]. Another randomized study performed
by Tzanetakou et al. two years later compared the disease
activity in 20 participants with HS who were assigned at
random to a daily injection of either Anakinra or placebo.
The group treated with Anakinra showed decreased disease
activity and prolonged remission relative to placebo [35].
Pathogenesis-tailored therapeutics were also investigated in
the treatment of COPD. In 2004, Mahler et al. studied the
effect of neutralizing IL-8, a strong neutrophil chemotactic
factor, with a monoclonal antibody. The researchers reported
a symptomatic improvement of COPD in the treated group
compared to placebo [36]. Similarly, leukotrieneB4 inhibitors
and TNF-alpha blockers have shown promising results in
halting COPD progression [37]. HS lung comorbidities are
summarized in Figure 1.
2.3. Pyoderma Gangrenosum (PG) and Associated
Respiratory Comorbidities
2.3.1. Pyoderma Gangrenosum. Pyoderma gangrenosum is a
rare inflammatory neutrophilic dermatosis most commonly
presenting with a disfiguring deep necrotic laceration with
a dusky, indeterminate edge, typically in the lower limb. In
addition to the classic ulcerative presentation, four other
variants are identified: pustular, bulbous, peristomal, and
vegetative [38–41]. Since neither the clinical nor histological
manifestations are pathognomonic, PG is usually diagnosed
by a combination of features only after exclusion of other
conditions [16].
The pathogenesis of PG is complex and not yet fully
understood. Its foundational mechanism is believed to be
because of a pathological uncontrolled sterile neutrophilic
infiltration of the skin, and presumably other organs, in a
genetically predisposed individual [42]. Additionally accu-
mulating data support the role of autoinflammation in dis-
ease development. Aberrant signals involved in neutrophil
trafficking, chemotaxis, metabolic activity, and phagocytic
function are among the main driving mechanisms of PG.
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Figure 1: Hidradenitis suppurativa and its described respiratory comorbidities.
This possibly explains its common association with other
dysfunctional neutrophil-driven systemic disorders. Over-
expression of neutrophil chemotactic factors such as IL-
8 in cutaneous lesions further consolidates the idea of
neutrophils playing a key role in PG. Additionally, PG
lesions show high levels of MMP, TNF-alpha, and IL-17.
Further favoring the idea of autoinflammation as the nidus
of PG comes with the discovery of proline-serine-threonine-
phosphatase interactive protein (PSTPIP-1) mutation. This
was recently identified in PG-associated syndromes, namely,
PAPA (pyogenic arthritis, pyoderma gangrenosum, and acne)
and PAPASH (pyogenic arthritis, pyoderma gangrenosum,
acne, and hidradenitis suppurativa), each of which includes
PG aswell as at least one other neutrophilic systemic disorder.
Normally the CD2-binding protein encoded by the PSTPIP-
1 gene binds pyrin resulting in suppressed inflammasome
activation and proinflammatory cytokine production. This
loss of function mutation therefore releases the inflamma-
some from its default inhibition leading to autoactivation
of a caspase-1 cascade and triggering a vicious cycle of
IL-1𝛽 overproduction and enhanced neutrophil recruitment
and activation. Further supporting the autoinflammation
hypothesis is the recognition of upregulation of IL-1𝛽 and its
receptors in these cutaneous eruptions [43, 44].
2.3.2. PG and Extracutaneous Respiratory Involvement.
While the exact etiology of PG remains idiopathic, its
occurrence is frequently associated with other serious
chronic inflammatory conditions, such as inflammatory
bowel disease, hematological malignancy, and rheumatoid
arthritis, and therefore physicians should maintain vigilance
looking for themwhen a case of PG is diagnosed [39]. Among
the rare yet significant extracutaneous manifestations of
PG are those involving the respiratory system. Till 2018,
only forty-one cases of this comorbidity were described in
the international literature [45]. Cutaneous lesions usually
precede the pulmonary manifestation, which is sometimes
diagnosed several years later after excluding other diagnoses
such as lung cancer andWegner’s granulomatosis. Symptoms
observed range from cough, dyspnea, hemoptysis, and low
grade fever to stridor and fulminant alveolar hemorrhage.
Findings on chest X-rays and CT scans of most of these
patients demonstrate unilateral or bilateral nodular infiltrates
sometimes progressed to cavitation with no predilection
of specific lung zone of location. These are sometimes
mistaken for lung abscess. Additionally, opacities and
pleural effusions were reported as well. The predominant
histological feature was neutrophilic infiltration which is
in agreement with the neutrophil being the main culprit
in the extra cutaneous manifestations. Lesions in the lung,
however, rarely show necrotizing granulomas or vasculitis.
Additionally, overexpression of IL-17 was recorded in both
cutaneous and pulmonary conditions. IL-17 stimulates the
production of IL-1𝛽 and TNF-𝛼 from macrophages and
induces the production of neutrophil chemoattractants from
human bronchial epithelial cells [46, 47]. Furthermore,
a dramatic improvement of the pulmonary condition
was reported after the proper treatment of PG with high
doses of steroids or immunosuppressants, which further
supports the hypothesis. Therefore physicians should be
aware of these well-established associations and perform a
thorough examinations for every patient with PG to rule
out comorbidities [39, 47]. PG respiratory comorbidities are
resumed in Figure 2.
2.3.3. Implications ofThis Association on Treatment Strategies.
Physicians usually follow a stepwise approach in managing
PG with the mainstay therapy being immune suppressants
such as ciclosporin and corticosteroids, and the choice among
them will usually be decided based on local experience.
However, promising data on newer targeted treatment such
as TNF-𝛼 inhibitors, IL-1 beta, and IL-8 blocking agents
continue to be reported; this is particularly true for refractory
cases not responding to conventional therapy [38]. In an
open-label study conducted by Kolios et al., 2015, treat-
ment of five patients with PG lesions resistant to steroids
with canakinumab (monoclonal antibody against IL-1𝛽)
resulted in complete resolution in three patients and partial
improvement in one patient after 16 weeks of treatment [48].
Additionally, in 2017, three recalcitrant cases with PG and
8 BioMed Research International
NODULES
and
NEUTROPHILIC
INFILTRATES
CYSTS
PLEURAL
EFFUSION
Figure 2: Respiratory comorbidities of pyoderma gangrenosum.
Table 2: Major and minor criteria for the diagnosis of Sweet
syndrome.
Major Criteria
(1) Clinically: sudden eruption of tender erythematous papules,
coalescent plaques, or nodules commonly affecting face, neck, and
the upper limbs
(2) Histologically: extensive dermal neutrophilic infiltrate and
edema in the absence of leukocytoclastic vasculitis
Minor Criteria
(1) Fever > 38∘C
(2) Preceded by vaccination or URTI∗ or GIT∗ infections,
associated malignancy ( visceral or hematologic) or pregnancy
(3) Dramatic response to systemic steroids or potassium iodide
(4) Abnormal lab∗ values at presentation (three of four):
ESR∗ >20 mm/hr; positive CRP∗; WBCs∗ >8,000; >70%
neutrophils)
URTI: upper respiratory tract infections, GIT: gastrointestinal tract, ESR:
erythrocyte sedimentation rate, CRP: C reactive protein,WBCs: white blood
cells.
rheumatoid arthritis or systemic lupus erythematosus were
successfully treated with Anakinra, IL-1 receptor antagonist
[40]
2.4. Sweet Syndrome and Respiratory Comorbidities
2.4.1. Sweet Syndrome (Acute FebrileNeutrophilic Dermatoses).
Sweet’s syndrome, also referred to as acute febrile neutro-
philic dermatosis, was first introduced by Dr. Robert
Douglas Sweet in the British Journal of Dermatology
in 1964 [49]. Sweet syndrome can be divided based on
association(s) or preceding event(s) into three subtypes:
(a) Classical Sweet syndrome (b) Malignancy-associated
Sweet syndrome (c) Drug-induced Sweet syndrome [50, 51].
The syndrome’s major defining criteria are based on the
typical clinical and histological features required to make
the diagnosis in all types, along with two additional
minor findings [50] (Table 2). Rash is often preceded
by bacterial upper respiratory infection, especially of
streptococcal origin [50, 52]. This may be explained by
either a hypersensitive reaction to the microbial antigen or a
consequence of bacterial-induced overproduction of
granulocyte-macrophage colony-stimulating factor (GM-
CSF) and granulocyte colony-stimulating factor (G-
CSF). This outcome is further supported by the reported
development of Sweet syndrome following treatment with
these cytokines (GM-CSF, and G-CSF). The implication of a
perfunctory bacterial relationship should raise awareness of
the importance of first treating the bacterial infection with
antibiotics before rushing into the use of corticosteroids with
potential side effects [53, 54]. In addition, Sweet syndrome
sometimes develops after the use of certain medications,
such as all transretinoic acids, adalimumab, ipilimumab,
vemurafenib, azathioprine, and some antibiotics. To make
a drug-induced diagnosis, the presenting rash should be
reproducible with the recurrent use of the same drug and
spontaneously resolve upon its withdrawal [50, 55–57]
(Wallach and Vignon-Pennamen, 2015, and Vashisht and
Holmes, 2017).
Pathogenesis of Sweet syndrome is still not fully delin-
eated. It has been related previously to altered immune
response or possibly hypersensitivity to microbial or neo-
plastic antigens [52]. Recently, a potential link to autoinflam-
matory underpinnings has gained support through various
genetic and molecular discoveries. Modified transcription
or function of genes involved in the regulatory signaling
pathway of hematopoietic stem cells, such as tyrosine protein
phosphatase nonreceptor type 6 gene (PTPN6), has been
described. This possibly explained paraneoplastic associa-
tions of Sweet syndrome with hematogenous malignancies
and/or chronic inflammatory conditions [14, 58]. Further-
more, overexpression of IL-1B, master of the proinflamma-
tory cytokines, along with neutrophilic chemotactic factor,
IL-8, is described in Sweet cutaneous and extracutaneous
lesions. Also of note, the differential levels of their expression
correlate with the various levels of severity observed not only
across the spectrum of neutrophilic dermatoses but also on a
case to case basis [14, 55, 59]. Pulmonary findings seem to be
relatedmainly to the classical andmalignancy-associated Sweet
syndrome and usually follow cutaneous manifestations.
2.4.2. Sweet Syndrome and Pulmonary Neutrophilic Infiltrates.
From 1981 to 2015, forty-three cases of Sweet syndrome-
associated pulmonary involvement were reported in the
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literature, of which 11 had exclusively respiratory extracu-
taneous manifestations. Notably, the other 31 also suffered
from multiple other comorbidities. Sweet’s rash preceded
lung symptoms in 6 cases, while the other 5 of 11 patients
complained of the respiratory condition first. Imaging work
most frequently revealed interstitial lung opacities that can
be unilateral [60–72] or bilateral [73–84] with or without
pleural effusions and no site or lobe predilection [78, 85, 86].
A presenting scenario such as this can be easily confused
with pneumonia especially when a biopsy from the lesions is
not feasible in critically ill patients, those prone to bleeding
or other high risk complications [72, 87]. Sampling from
skin and lung lesions reveals sterile polymorphonuclear
infiltrates [60–62, 68, 70, 71, 73–75, 77, 79, 82–85, 88] in
most of the cases, further indicating the role of systemic
neutrophil contribution in the development of extracuta-
neous manifestations in the lung and elsewhere (Takimoto
et al., 1991, Yang et al., 2015, Syed et al., 2018) [61, 72,
87]. Outcomes of Sweet-associated pulmonary conditions
vary broadly from rapid improvement with corticosteroid
treatment to serious pulmonary compromise and respiratory
failure. In 1991 Takimoto et al. described a case with repeated
episodes of acute febrile neutrophilic dermatosis with inter-
stitial nodular pulmonary infiltrates who at first responded to
steroid therapy but became progressively resistant to steroid
and ultimately died from respiratory complications [61]. A
similar outcome was recorded in 4 other cases [70, 71, 77, 79].
In the context of the evidence presented, even though lung
involvement has been rarely reported with Sweet syndrome,
the potential development of life-threatening pulmonary
complications should be taken into consideration particularly
after pneumonia is excluded and antimicrobial treatments
have failed [61, 87].
At least 3 additional cases were reported subsequently
[51, 87, 89], including a case of acute neutrophilic dermatosis
developed in a patient with pulmonary tuberculosis [51]. In
view of the above, a crucial distinction should be made as to
whether the cutaneous eruption is secondary to themycobac-
terial infection or is a primary skin conditionwith pulmonary
symptoms. In the scenario where the lung infection is the
primary established diagnosis, systemic steroid should be
used with caution to avoid the risk of dissemination of a
localized tuberculosis or the activation of a latent infection.
Colchicine can be used as an effective and safe substitute [51].
2.4.3. Sweet Syndrome and Lung Cancer. Sweet syndrome
is frequently described in association with hematogenous
malignancy such as chronicmyeloid leukemia and lymphoma
[50, 54, 90–96]; because of this frequent finding many sci-
entists deem it a paraneoplastic phenomenon [92]. However,
while this association is well established for liquid tumors,
it is rare with solid tumors including lung cancer. Only
seven cases were published describing an association between
Sweet syndrome and lung cancer [95]. The first case with
lung adenocarcinoma was described by Nielsen et al. in
1993 [92] and one year later Yamamoto et al. identified the
first case with small cell lung cancer [93]. It was postulated
that paraneoplastic production of IL-8, G-CSF, and GM-
CSF by malignant cells was responsible for the extensive
recruitment of PMN leukocytes to the skin, accounting for
the development of Sweet’s syndrome [97]. Moreover, with
the progressive increase in both the incidence and annual
deaths from lung cancer, much research is dedicated to fully
unravel the pathogenesis of this neoplasm, which may lead
to a greater appreciation of the role of neutrophils in this
condition. In addition, animal studies as well as Bronchoalve-
olar lavage (BAL) from patients with lung cancer reveal an
upregulation of neutrophil infiltrate in tumor lesions, which
is higher in lung squamous cell carcinoma when compared to
adenocarcinoma. Furthermore, in addition to maintaining a
state of chronic inflammation, which by itself is an important
risk factor for cancer development, the neutrophils, after
entering the cells, produced elastase which may further
contribute to the pathogenesis of lung cancer by induc-
ing mitogenesis. Lastly, assessing the neutrophil/lymphocyte
ratio (NLR) can provide prognostic value in both small
and non-small lung cancers. A high NLR is associated with
poor clinical outcome and decreased overall survival rate.
In view of the aforementioned, the potential paraneoplastic
connection of Sweet syndrome with hematogenous as well
as solid tumors should be taken into account and a full
work-up for malignancy should be considered, particularly
for older individuals with other risk factors [28]. Respiratory
comorbidities of Sweet syndrome are summarized in Figure 3.
2.4.4. Implications ofThis Association on Treatment Strategies.
Although the most common treatment of Sweet syndrome
remains systemic steroids, the increasing number of fulmi-
nant refractory cases together with the recent advances in the
molecular pathogenesis have introduced targeted treatment
as a safer, more precise, and effective therapy. Delluc et
al. were the first to report a dramatic efficacy of Anakinra
in the treatment of a recalcitrant case of Sweet syndrome
with alveolar lung condensation [98]. In 2011, Anakinra
was successfully used in the treatment of another resistant
case. This shed light not only on the promising role of
the IL-1 receptor antagonist in the treatment of refractory
cases with comorbidities, but also on the importance of
the autoinflammation and the inflammasome theory in the
etiopathogenesis of Sweet syndrome [99].
2.5. Subcorneal Pustular Dermatosis and Associated Respira-
tory Conditions
2.5.1. Subcorneal Pustular Dermatosis (SPD). Subcorneal
pustular dermatosis (SPD) is a rare chronic relapsing der-
matosis, first described by Sneddon and Wilkinson in 1956
[100]. The presence of the following criteria is necessary
for diagnosing SPD: new onset symmetrical, flaccid pustular
eruption distributed in a gyrate pattern healed with annular
shaped scale predominantly involving flexural aspect of trunk
and intertriginous regions, histologically characterized by a
sterile subcorneal neutrophilic infiltrationwithout spongiosis
or acantholysis, and an excellent response to dapsone treat-
ment. Differential diagnosis includes SPD-type IgA pemphi-
gus and pustular psoriasis which can be distinguished by
immunological studies. SPD has been reported in association
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Figure 3: Respiratory manifestations of Sweet syndrome.
with many extracutaneous disorders including hematoge-
nous conditions such as multiple myeloma, lymphoma, and
monoclonal gammopathy, inflammatory bowel disease, and
infections like mycoplasma pneumoniae [9, 101–103].
2.5.2. Mycoplasma pneumoniae. Mycoplasma pneumoniae
mainly affects respiratory airways with the majority of cases
being self-limited. It has recently been proven that the
severity of pneumonia caused by M. pneumoniae depends
primarily on innate immunity. Severe infections have a
substantial neutrophilic infiltration compared to the recovery
stage which showed a marked reduction in the number of
polymorphonuclear leucocytes [28, 104].The clearance of the
pathogen is thought to beTh17 driven as opposed toTh1 and
Th2 cells, as was demonstrated by Wu et al. IL-17 production
is essential in neutrophil recruitment and activity in the lung
defense against M. pneumoniae infection, so it is plausible
to hypothesize that a dysregulated Th17 immune response in
genetically predisposed individuals will result in perpetual
recruitment and activation of neutrophils resulting in a severe
pneumonia [105].
In addition, M. pneumonia is notorious for extrapul-
monary involvement in at least 25% of cases with the
majority including cutaneous and mucosal manifestations
that can sometimes present without any preceding respi-
ratory symptoms. The mechanism of such associations can
be explained by cytokine mediated local inflammation or
indirect modulation of immune response and deposition of
immune complexes [104, 105].
2.5.3. Association of SPD with M. Pneumoniae. Until 2015,
nine cases of SPD have been described in association with
M. pneumoniae respiratory infections. This has been related
to the indirect effects of the organism on host innate
and adaptive cell mediated immunity, potentially through
upregulation of neutrophilic chemotaxis and activation in
M. pneumoniae which triggers the development of SPD
[31, 106–113]. Further supporting the role of neutrophils
in this association is the dramatic response of SPD to
dapsone. Dapsone works through the inhibition of integrin
mediated neutrophilic adherence and chemotaxis [102, 114].
Additionally, this association should draw attention to the
possibility of M. pneumoniae being manifested as pustular
and bullous skin conditions. Importance must be given to the
screening for the infection in patients presenting with these
rare blistering dermatoses and particularly being aware of the
benign course of the associated cutaneous condition which
does not necessitate systemic treatment [101, 112].
2.6. Pustular Psoriasis and Respiratory Comorbidities
2.6.1. Pustular Psoriasis. Pustular psoriasis is an uncommon
variant of psoriasis vulgaris, a chronic systemic inflammatory
disease [115–117]. It is known for its cutaneous and extracuta-
neous manifestations, which presents clinically as superficial
sterile pustular eruption on erythematous base [118]. Pustular
psoriasis can manifest as a localized entity in cases of
palmoplantar pustular psoriasis and Acrodermatitis continua
of Hallopeau or in a generalized diffuse life-threatening form
as seen with infantile and juvenile pustular psoriasis, pustular
psoriasis of pregnancy, and generalized pustular psoriasis
(GPP). Whether it is localized or generalized, all subtypes
of pustular psoriasis share the same histological features.
These include parakeratosis, extensive polymorphonuclear
inflammatory infiltrate, that can cluster anywhere in the
epidermis including stratum corneum, also known as Munro
microabscess, spinous zone in association with spongiosis,
referred to as spongiform pustules of Kogoj, atrophy of stra-
tum granulosum, and dilated tortuous papillary capillaries
responsible for Auspitz sign of psoriasis [119, 120].
2.6.2. Pustular Psoriasis Triggered by URTIs. Upper respira-
tory tract infections (URTIs), especially streptococcal tonsil-
litis, are one of the most frequently reported triggers for the
development of generalized as well as infantile and juvenile
pustular psoriasis variants.This could be related to genetically
determined hypersensitivity to microbial antigens [120–122].
In a prospective cohort study including 3994 subjects with
psoriasis and 10000 matched healthy controls conducted by
Huerta et al. in 2007, S. pyogenes was isolated from up to 97%
BioMed Research International 11
COPD: Chronic Obstructive Pulmonary Disease.
ASTHMACOPD
PNEUMONIA
STERILE
Figure 4: Respiratory comorbidities described in the context of pustular psoriasis.
of psoriatic patients aged between 21 and 40 years [123]. In
another study performed by Seyhan et al. in 2006,URTIswere
reported as themost commonpredisposing factor of psoriasis
in childhood and adolescents [124]. Reported precipitating
factors include corticosteroid withdrawal, vaccines, and some
antibiotics [120].
Pathogenesis of pustular psoriasis is still not fully under-
stood; however recent evidence points to it being an autoin-
flammatory disorder based on genetic and immunological
studies with a hallmark of overexpression of IL-1 cytokines
or disinhibition of their signaling pathway [125]. The genetic
deficiency of IL-36 receptor antagonist (IL-36RN), also
referred to as DITRA recently identified in all familial cases
and few sporadic cases of GPP, has further supported this
hypothesis. IL-36RN, predominantly expressed in skin, acts
to antagonize three IL-36 cytokines, all of which belong to
the proinflammatory IL-1 family, the main effector molecule
in the pathogenesis of autoinflammation [126]. Respiratory
comorbidities described in pustular psoriatic patients are sum-
marized in Figure 4.
2.6.3. Pustular Psoriasis and Sterile Pneumonitis. Remark-
ably, subclinical inflammation in psoriatic patients, with-
out respiratory diagnosed comorbidities, [127, 128] was
highlighted recently by the use of fraction exhaled nitric
oxide, a noninvasive tool routinely used in diagnosing and
monitoring asthma and COPD [129–131]. Although rare,
pulmonary complications described with pustular psoriasis
can be life threatening and therefore require awareness and
immediate intervention [132–134]. Among these fulminant
conditions is the sterile pneumonitis, a respiratory nonin-
fectious acute respiratory distress syndrome associated with
GPP, first described by Landry and Muller in 1972 [135].
Until 2011, thirteen cases [99, 135–142] were described in
the literature. All cases presented with a rapidly progressive
deterioration in respiratory functions, manifested as dyspnea
and severe hypoxemia that were preceded by acute flare of
their cutaneous condition. Another cardinal feature of this
association was the significantly high level of neutrophilia
reported in all patients. Imaging studies including chest X-
ray and CT scan with contrast revealed bilateral intersti-
tial and alveolar infiltrate. The condition was differentiated
pneumonia and congestive heart failure caused by the lack
of effectiveness of empirical broad spectrum antibiotics
and loop diuretics, respectively. In addition hypersensitivity
to commonly prescribed psoriasis medications was also
excluded. The outcome was generally bad except for those
who immediately initiated on a high dose of corticosteroids.
As an explanation of this association, cases’ reporters have
postulated a role of high level of circulating proinflammatory
cytokines in particular TNF-alpha in themassive recruitment
ofmononuclear and polymorphonuclear cellswith a resultant
extensive alveolar inflammation and capillary leak [99].
2.6.4. Psoriasis and COPD. A population-based case control
study conducted by Dreiher et al. in 2008 investigated the
association between psoriasis and COPD [143]. According to
the authors, the prevalence of COPDwas significantly higher
among psoriatic subjects compared to controls. Additionally,
two meta-analyses have recently reviewed the correlation
between psoriasis and COPD [144, 145]. According to both
meta-analyses there was a significant higher susceptibility
to COPD in psoriatic patients when compared to controls.
The mechanism of this association was explained by the
fact of both conditions being chronic inflammatory diseases
with an imbalance between the proinflammatory activity
of Th17 and the anti-inflammatory role of Treg with an
overexpression of IL-17A and IL-17F in both conditions. IL-
17 is known to trigger and amplify a neutrophilic mediated
immune response. Also, of note, IL-36, one of the cardinal
psoriatic cytokines, has been found to be elevated in the
COPD patients’ lavage. Furthermore, a defect in the signals
controlling polymorphonuclear chemoattraction and elastase
release was linked to mucin hypersecretion and a compro-
mised lung function. Consistent with this explanation was
the finding of an excessive level of proinflammatory cytokines
such as TNF-alpha, IL-6, and IL-8 in circulation. In view of
this association, dermatologists should advise their patients
about the importance of smoking cessation and the avoidance
of other risk factors that can further positively feed this
inflammation loop [143, 146].
2.6.5. Psoriasis and Asthma. Only few studies have high-
lighted the increased risk of developing asthma in psoriatic
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patients. A population-based retrospective cohort study with
10288 recruited psoriatic subjects has revealed a significant
increase risk of asthma in patients suffering from psoriasis
[147]. A meta-analysis performed recently by Wang et al.,
including a total number of 66,772 patients with psoriasis,
has shown an increased susceptibility of asthma among
these patients [148]. Asthma is now considered a general
term and defined as a state of airway hyperresponsiveness
with subsequent inflammation and reversible obstruction.
This umbrella includes many entities depending on the
predominant leukocytic infiltrates. Dysregulated activity of
Th17 cells, mediated by proinflammatory cytokines such as
IL-1𝛽, IL-6, IL-23, and TGF𝛽, was proposed as a crucial
trigger and amplifier of both cutaneous and airway inflam-
mation especially neutrophilic asthma, a hypothesis further
supported by the efficacy of blocking Th17 cytokines such as
IL-12/IL-23 in controlling both conditions, in particular those
that were not responsive to conventional therapy [148–150].
3. Conclusion
Since the first reported case of PG in 1908, research unrav-
eling the etiopathogenesis of neutrophilic dermatoses has
continuously evolved. Given the frequent association with
extracutaneous manifestations where neutrophils seem to
play a crucial role, it is plausible to consider NDs as a
cutaneous presentation of a systemic neutrophilic condition.
Additionally, accumulating evidence suggests this entity of
dermatoses may be part of an autoinflammatory condition,
which is supported by the efficacy of IL-1 blockers in man-
agement of recalcitrant cases. Moreover, a prominent role
of an aberrant adaptive immune reaction with imbalance
between proinflammatory Th17 and anti-inflammatory Treg
immune responses was described; this was underpinned by
the overexpression of cytokines involved inTh17 polarization.
In the previous correlations summarized in this review,
pulmonary involvement was not uncommonly reported with
NDs. Associated respiratory condition can serve to be a trig-
ger, as seenwithURTIs frequently preceding the rash of Sweet
syndrome and pustular psoriasis. Similarly M. pneumoniae
infection was frequently reported with the rare entity of SPD
so that SPD was referred to as the cutaneous manifestation
ofM. pneumoniae. At other times, respiratory symptoms can
develop or be exacerbated secondary to the uncontrolled
skin disorder as is the case with asthma and COPD whose
risk was significantly higher with pustular psoriasis and HS.
Furthermore, life-threatening complications were recounted
in association with NDs such as the development of ster-
ile pneumonitis described more than once with pustular
psoriasis. Many potential mechanisms were postulated to
explain this association. These include aberrant neutrophil
chemotaxis and activation that was either connected to a
genetic defect in innate immunity such as autoinflammation
or tied to a dysregulated adaptive immune response with
excessiveTh17 polarization or a paraneoplastic phenomenon.
In view of the above, it is important to apply this knowledge in
the three steps of patients’ management, work-up, diagnosis,
and treatment. Given the well-established paraneoplastic
association, a thorough work-up to rule out hematogenous as
well as solid malignancy is crucial in every patient especially
when other risk factors coexist. Additionally, while making
the diagnosis, it is important to define the chronological
order of the conditions and determine whether the ND is
the primary event or the consequent condition. This was
the case with pulmonary tuberculosis reported with Sweet’s
syndrome, where therapy was directed toward primarily
controlling the respiratory infection before rushing into
high doses of corticosteroids to treat the cutaneous disease.
Physicians should be aware of the systemic associations of
NDs including the respiratory conditions whichmay redirect
their therapeutic strategies either to address both conditions
with one treatment or to avoid the exacerbation of one disease
while attempting to treat the other [6].
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